Eloxatin generic version to be ceased from sale by Sun Pharma

According to the medicine manufacturing firm in India, Sun Pharmaceutical Industries, it is set to cease putting on sale Sanofi-Aventis’ cancer medicine Eloxatin’s generic version in the United States starting June 30, 2010 to August 2012 as commanded by the court.

Pfizer targets two-digit sales increase this calendar year

According to the Managing Director of Pfizer Ltd, Kewal Handa, the pharmaceutical company has been looking forward to a two-digit sales increase this current calendar year. Moreover, the firm’s sales increased 19% in the same period last year concluding last May.

61.47% ownership assured by Khorakiwala Holdings: Wockhardt

According to Wockhardt, Khorakiwala Holdings & Investments Private has already committed 67 million shares or 61.47% ownership in the firm which brings its total stake to 96.49%. Moreover, the Chairman HF Khorakiwala already committed 0.4% stake or 0.44 million stake.

Parabolic Drugs scheduled to launch IPO in June 14

Parabolic Drugs recommends to embark on principal trade exchanges by means of an initial public offer or IPO of equity shares in order to accumulate fund with utmost value of Rs 200 crore. Moreover, the IPO is scheduled on June 14, 2010 to be launched and subscribed. The conclusion is on June 16-17, 2010.

Ranbaxy Labs introduces atorvastatin in South Africa

The leading medicine manufacturing firm of India based on sales, Ranbaxy Laboratories, announced that the firm has already introduced atorvastatin, drug counterpart in Africa of Pfizer Inc’s Lipitor. Moreover, the market size in South Africa for this medicine has a value of around USD 26 million.

Jyothy Labs witnesses increases in top-line, PAT last Q4

According to the Deputy Managing Director of Jyothy Labs, K Ulhas Kamath, the firm already released its fourth quarter outputs in the financial year 2009-2010 wherein its top-line increased 30% while its PAT or profit after tax rose around 38%. Moreover, the profit grew twofold and its PBT rose to nearly Rs 100 crore.

Ranbaxy eyes USD 100 million 2010 revenue from South Africa units

According to Atul Sobti of the medicine manufacturing firm in India, Ranbaxy, the conglomerate has been looking forward to its revenue from South Africa business this calendar year to reach USD 100 million which is a USD 25 million more than its 2009 recorded revenue.

Ind Swift Labs achieves Rs 780 crore cons revenues in FY10

According to the Vice Chairman of Ind Swift Labs, NR Munjal, the pharmaceutical company already announced its fourth quarter outputs in the financial year 2009-2010 wherein its consolidated revenues was recorded at Rs 780 crore while its consolidated net profit rose to Rs 51 crore from Rs 35 crore.

Voltas, Gayatri Projects, Rane Holdings, Indian Oil Corporation declared results today

Oil and Natural Gas Corporation
Net profit was up at Rs 3,776 crore versus Rs 2,207 crore
Net sales were up at Rs 14,713 crore versus Rs 13,704 crore

Voltas
Net profit was up at Rs 381 crore versus Rs 251 crore
Net sales were up at Rs 4,806 crore versus Rs 4,326 crore

Nectar Lifesciences
Net profit was up at Rs 92 crore versus Rs 45 crore

Fresenius Kabi Oncology
Net profit was at Rs 80.2 crore

Gayatri Projects
Net profit was up at Rs 15 crore versus Rs 11 crore
Net sales were up at Rs 377.2 crore versus Rs 333.9 crore

Steel Authority of India
Net profit was up at Rs 2,084 crore versus Rs 1,485 crore
Net sales were up at Rs 12,229.7 crore versus Rs 11,986 crore

Rane Holdings
Net profit was up at Rs 41.6 crore versus Rs 16.5 crore

Housing Development and Infrastructure
Net profit was up at Rs 177.84 crore versus Rs 162.76 crore

Indian Oil Corporation
Net profit was down at Rs 5,557 crore versus Rs 6,623 crore
Net sales were up at Rs 66,116 crore versus Rs 59,596.7 crore

Dredging Corporation India
Net profit was at Rs 70 crore
Net sales were at Rs 645 crore

Hanung Toys and Textiles
Net profit was up at Rs 33.28 crore versus Rs 23.08 crore

Glenmark Pharma attains Rs 491 crore net sales in Q4 FY10

According to the Chief Executive and Managing Director of Glenmark Pharmaceuticals Ltd, Glenn Saldanha, the firm already announced its Q4 outputs in the financial year 2009-2010 wherein its consolidated net profit was recorded at Rs 102 crore in quarter until March while its net sales stood at Rs 491 crore YoY.

Sabero Organics PAT in Q4 FY10 increases to Rs 7.25 crore

According to the Vice Chairman of Sabero Organics, Sumit Chuganee, the firm already declared its fourth quarter outputs in the financial year 2009-2010 wherein its revenue decreased from Rs 98.85 crore to Rs 96.57 crore in the same period last year. Its PAT increased from Rs 0.99 crore to Rs 7.25 crore.

Bafna Pharma eyes Rs 120 million industry from Ethiopia

According to the Chairman and Managing Director of Bafna Pharmaceuticals, Bafna Mahaveer, the pharma firm established in Chennai has been eyeing a minimum of Rs 120 million industry from Ethiopia in the present calendar year as it also concentrates its expansion in Asia and Africa.

Lupin Ltd obtains permission from US FDA for high blood pressure drugs

According to the website of the medicine supervisory body this Tuesday, it revealed that the pharmaceutical leading firm Lupin Ltd already obtained the nod by the US FDA for its losartan potassium as well as hydrochlorothiazide tablets wherein both drugs give medication to high blood pressure.

Sun Pharma absorbs 2.2% revenues slump in Q4 FY10

According to the Managing Director of the leading pharmaceutical firm Sun Pharma, Uday Baldota, the conglomerate already declared its quarter four outputs in the financial year 2009-2010 wherein its revenues slumped 2.2% from Rs 1,134.4 crore to Rs 1,109.2 crore in the same period last year.

Tata Chemicals, Kalyani Steels, Madras Cements, KRBL declared results today

Tata Chemicals
Net sales were down at Rs 9,448.49 crore versus Rs 12,153.31 crore

Kalyani Steels
Net profit was up at Rs 43.3 crore versus Rs 3.3 crore

Madras Cements
Net profit was at Rs 354 crore

Opto Circuits India
Net sales were at Rs 334.5 crore

Sun Pharmaceutical Industries
Net profit was at Rs 395 crore

KRBL
Net profit was at Rs 18 crore

Central Bank of India
Net profit was up at Rs 1,160 crore versus Rs 636 crore

Piramal Healthcare purchased by Abbott India

In a statement released by Miles D White, the Chairman and Chief Executive Officer of Abbott India, he confirmed that the firm already purchased Piramal’s Healthcare Solutions unit, Domestic Formulations, for an advance compensation of USD 2.12 billion plus an extra USD 400 million yearly until 2014.

Lipitor generic introduced in Canada by Ranbaxy Lab

In a statement released by Ranbaxy Laboratories, the biggest medicine manufacturing firm by sales in India, it has already introduced in Canada the Lipitor generic. Furthermore, the bulk-controlled unit of Daiichi Sankyo of Japan stated that Lipitor accounts for 1.2 billion Canadian dollars in the nation’s market.

Pyramid Healthcare (US) purchased by Avantha Group

In a statement released by Avantha Group, the conglomerate confirmed that it already purchased the American firm Pyramid Healthcare Solutions or PHS wherein it bought 100% stake in it with an amount of around USD 20 million. The advance payment of USD 14.5 million was settled up while the remaining by 2013.

Visa Steel, Camson Bio Technologies, Rural Electrification Corporation declared results today

Visa Steel
Net profit was at Rs 16.5 crore
Net sales were up at Rs 399 crore versus Rs 266 crore

Camson Bio Technologies
Net profit was up at Rs 23.5 crore versus Rs 2.5 crore

Rural Electrification Corporation
Net profit was up at Rs 561 crore versus Rs 388 crore
Net sales were up at Rs 1,796 crore versus Rs 1,337 crore

Dr Reddy’s obtains US regulator’s approval for tacrolimus capsules

Dr Reddy’s Laboratories, the top-two medicine manufacturing firm in India by sales, already obtained the nod from the US Food and Drug Administration, an American regulating body, this Thursday to introduce tacrolimus capsules which are utilized to aid avoid refusal of kidney and liver transplants.